News

1.23.24

Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies

10.10.23

Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium

9.21.23

Accent Therapeutics Bolsters Leadership Team with Key Executive Hires

4.16.23

Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023

4.6.23

Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023

10.18.21

Ipsen Adds Another Program Into Its Pre-clinical R&D; Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3

6.4.20

Accent Therapeutics and AstraZeneca to Discover and Develop Novel Cancer Therapeutics in New Collaboration

4.23.20

Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting Rna-modifying Proteins

Events

Mechanisms of DNA Repair, Replication, and Genome Rearrangements GRC

MARCH 10 - 15, 2024, VENTURA, CALIFORNIA

AACR Annual Meeting 2024

APRIL 5-10, 2024, SAN DIEGO, CALIFORNIA

Biophysics for Drug Discovery Summit

APRIL 22-24, 2024, BOSTON, MASSACHUSETTS